
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx Inc demonstrated a strong financial performance with total revenue exceeding consensus estimates by approximately $16 million, driven by an $8 million contribution from its IBS treatment, Ibsrela. The company highlighted a healthy 27% quarter-over-quarter growth when excluding one-time benefits, reaffirming peak U.S. revenue guidance of $750 million prior to patent expiration. Additionally, Xphozah's U.S. net sales surpassed consensus by around $3 million, indicating successful initial implementation of strategies to address changes in Medicare Part D coverage.
Bears say
Ardelyx Inc faces significant challenges in the near term due to the recent loss of Medicare Part D coverage for its Xphozah product, which could adversely affect its market penetration among a crucial demographic. The company has demonstrated some ability to adjust its strategy by targeting the non-Medicare patient population, but the absence of financial guidance for FY25 raises concerns about future revenue stability and growth prospects. This uncertainty may hinder investor confidence and negatively impact the stock's performance moving forward.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares